Hefei Medicine to Distribute Biohit Products in China | GenomeWeb

NEW YORK (GenomeWeb News) – Finnish biotech firm Biohit today announced a distribution agreement with Hefei Medicine covering China.

The deal covers the distribution and marketing of Biohit's diagnostic products. Financial and other terms of the deal were not disclosed.

Among the products covered by today's announcement are Biohit's GastroPanel blood-based biomarker tests. The tests are for screening and diagnosing Helicobacter pylori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.